Features ICC Melanoma 2020
HOW TO MANAGE TOXICITY AND ASSESS THE ANSWER TO IMMUNOTHERAPY IN MELANOMA PATIENTSThe immunological therapy of melanoma is going through a phase of great evolution, thanks to the important results obtained in many clinical studies, starting from 2010, following the introduction of antibodies against immunological checkpoints such as CTLA-4 and, in particular, PD -1.
The purpose of this project is to investigate the main scenarios of difficult management of melanoma patients treated with ant-PD-1 antibodies, through examples of interactive clinical situations.
Secure & Private
Your data is protected with industry-leading security protocols.
24/7 Support
Our dedicated support team is always ready to help you.
Personalization
Customize the app to match your preferences and workflow.
See the ICC Melanoma 2020 in Action
Get the App Today
Available for Android 8.0 and above